Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLARES: 5-ALA for Soft Tissue Sarcoma Resection
NCT06252727Phase 1Withdrawn
- Sponsor
- University of California, Davis
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in soft tissue sarcoma (STS), sponsored by University of California, Davis. Primary endpoint: Feasibility of 5-ALA-aided fluorescent visualization of STS versus surrounding tissues up to 2 years. Planned start Jul 2024; status: withdrawn.
02
Drugs
5-aminolevulinic acid
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06252727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252727.